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and other autoimmune diseases,4 and from chronic obstruc-
tive pulmonary disease5 and hypopituitary adults6 to the eld-
erly in general.7 Although inappropriate adipokine expression
may not be a prominent feature in these circumstances, car-
diovascular death is more probable all the same. Is there a
chance that inflammation is a more important culprit?4
CLINICAL EXPERIENCE
In a prospective, placebo-controlled double-blind inves-
tigation with 40 morbidly obese subjects, of which 13 were
preliminarily evaluated and 24 have completed the protocol,
either suffering or not from comorbidities, we were recently
able to demonstrate8 that CRP, along with serum amyloid A
(SAA), another acute phase protein, directly correlated with
initial blood glucose, serum lipids, and white blood cell count
(Table 1). All of these markers have been associated with
increased mortality in different population groups.2–7,9
Another point that deserves to be raised is treatment and
its impact on the reported aberrations. What are the thera-
peutic priorities, and which derangement is more amena-
ble to control?
Weight loss is not only imperative, it is theoretically
the best prescription. If excess adipose tissue is elimi-
nated, adipokines, including leptin, TNF-alpha, and IL-
6, will not be overexpressed; therefore, alleviation of in-
Table 1 - Correlations of C-reative protein and serum
amyloid A
Initial variable CRP SAA
Blood glucose r= 0.889 ***
Total cholesterol r= 0.422 ** r= 0.316 *
Triglycerides r= 0.466 ** r= 0.871 ***
HDL r= - 0.375 *
LDL r= 0.502 **
White blood cell count r= 0.612 *** r= 0.428 **
(*) p< 0.05; (**) p< 0.02; (**) p< 0.01.
INTRODUCTION
In the interesting clinical article by Bahia et al,1 obese
subjects with metabolic syndrome are prospectively com-
pared with lean controls. The addressed question is highly
relevant and up-to-date, namely, the relationship between
obesity with metabolic syndrome, inflammation, and se-
cretion of adipokines on one hand, and insulin resistance,
endothelial function, and vascular reactivity on the other.
They found out that the obese population displayed im-
paired vascular reactivity, and the 2 measured adipokines,
adiponectin and resistin, correlated with 1 vascular reactivity
variable each. Inflammation was prominent in this cohort (el-
evated C-reactive protein/CRP), but comparatively few cor-
relations were assigned to this measurement; just 1 adipokine
(resistin) and 1 component of the coagulation cascade, plas-
minogen activator inhibitor-1 (PAI-1), seemed to be involved.
One may thus speculate that if a link exists between CRP
and vascular reactivity, it is an indirect one, via resistin, but as
no such result is shown, statistical significance was probably
weak or absent. But why should one insist on this detail?
Inflammation, insulin resistance, hyperlipidemia, and
hypercoagulability surely bring to mind advanced obesity
with metabolic syndrome. Deranged endothelium-depend-
ent and independent vasodilation, along with an increased
risk for future cardiocirculatory events, fit very well in this
picture. Within this context, the authors feel confident1 in
attributing much prognostic importance to insulin resistance
and to abnormal resistin levels.
It is known, however, that chronic microinflammation, not
necessarily associated with insulin resistance and all severe
neuroendocrine and metabolic dysfunctions typical of ad-
vanced obesity, is a much larger problem involved in a vast
array of diseases, from renal failure2 to rheumatoid arthritis3
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sulin resistance and dyslipidemia will follow, and inflam-
mation and hypercoagulability should regress, all at the
same time. Nevertheless, this is easier said than done, and
tangible results are not achieved in the short term, but only
after substantial time and effort. Furthermore, not all
physiological disturbances and comorbidities fully re-
spond to weight reduction.10   That is why secondary pre-
vention of cardiovascular events often comprises
pharmacologic intervention.
Aiming to get a better insight into the pathophysiology
of microinflammation, and to test the hypothesis that nu-
trients may be safe, inexpensive, and effective, in the same
protocol8 we introduced flaxseed flour (Farinha de linhaça
dourada, Linolive, CISBRA, São Paulo) into the diet. This
is a rich source of the vegetable omega-3 fatty acid alpha-
linolenic acid (ALA) (30 g of supplement/day corresponded
to 5 g of ALA), which is subsequently converted by the
liver into eicosapentaenoic acid (EPA), and it is recom-
mended by the American Heart Association for patients
without coronary disease.11 Within 2 weeks, alleviation of
inflammation according to both markers, CRP and SAA,
was clearly achieved.
It is worth mentioning that although resistin was not
monitored in the study, no change in body weight or tests
for glucose, insulin, leptin, or lipids were detected. It is there-
fore unlikely that insulin resistance influenced any results.
FINAL CONSIDERATIONS
Reduced long-term morbidity and mortality would be the
final proof that one is following the correct pathophysiologi-
cal path. Experience with ALA is relatively recent, but ma-
rine omega-3 fatty acids, which were introduced decades ago,
fulfill this requirement. They diminish coronary artery disease,
fatal and nonfatal myocardial infarction, sudden cardiac death,
and all-cause mortality.11–14  Indeed, protection against sud-
den death after myocardial infarction can be achieved with
supplementation for as little as 3 months13
Of course, causes of cardiovascular morbidity and mortality
can hardly be encompassed by a single trigger or key mechanism.
Antiplatelet action, angiotensin inhibition, and lipid lowering may
be advantageous, and it is recognized that intake of ALA by itself,
besides being anti-inflammatory, shifts the polyunsaturated fatty
acid metabolic pathway to EPA, thus favoring the formation of
products with a predominant anti-aggregating and vasorelaxing ac-
tion.14 The importance of stabilization of vulnerable atherosclerotic
plaques, progression of atherosclerosis, hemostatic activity, and vas-
cular inflammation as well as the potential influence of omega-3
fatty acids have been recently debated as well.15
Still, there are reasons to believe that the role of inflam-
mation in cardiovascular morbidity and mortality should be
more emphasized, both in obesity/metabolic syndrome and in
multiple other illnesses. By the same token, anti-inflamma-
tory maneuvers should be attempted in this setting.
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